Objective. Receptor for advanced glycation end products (RAGE) is a cell surface molecule that binds a variety of ligands, including high mobility group box chromosomal protein 1 (HMGB-1), a potent proinflammatory cytokine. RAGE-ligand interaction leads to an inflammatory response. A truncated form of the receptor, soluble RAGE (sRAGE), has been suggested to function as a decoy abrogating cellular activation, but its endogenous activity is not fully understood. We undertook this study to assess the properties of sRAGE in vivo and in vitro and to analyze the role of sRAGE in HMGB-1-induced arthritis.Methods. Mice were injected intraarticularly with HMGB-1 and treated systemically with sRAGE prior to histologic joint evaluation. All animals were subjected to peritoneal lavage to assess the local effect of sRAGE treatment. For in vitro studies, mouse splenocytes were incubated with sRAGE followed by assessment of NF-B activation and cytokine production. The chemotactic properties of sRAGE were investigated using in vitro migration assay.Results. Soluble RAGE was determined to have proinflammatory properties since it gave rise to production of interleukin-6, tumor necrosis factor ␣, and macrophage inflammatory protein 2. This effect was triggered by interaction with leukocyte 2 integrin Mac-1 and was mediated via NF-B. Systemic treatment with sRAGE significantly down-regulated HMGB-1-triggered arthritis, but the observed effect was due to a deviation of the inflammatory response from the joint to the peritoneal cavity rather than a genuine antiinflammatory effect. Apart from its proinflammatory properties, sRAGE was proven to act as a chemotactic stimulus for neutrophils.
Conclusion. We conclude that sRAGE interacts with Mac-1, thereby acting as an important proinflammatory and chemotactic molecule.The receptor for advanced glycation end products (RAGE) is a multiligand member of the immunoglobulin superfamily, being expressed as a cell surface molecule and playing a key role in diverse inflammatory processes (1). RAGE was first described as a receptor for "advanced glycation end products" (AGEs), the products of nonenzymatic glycation and oxidation of proteins and lipids that accumulate in the setting of diabetes (2). The receptor protein is composed of 3 immunoglobulin-like regions, a transmembrane domain, and a highly charged short cytosolic tail that is essential for intracellular signaling. The V domain in the extracellular part of the receptor protein is critical for ligand binding and interacts with a diverse class of ligands due to its ability to recognize 3-dimensional structures rather than specific amino acid sequences (3). Studies have shown that engagement of RAGE by its ligands results in a rapid and sustained cellular activation. Sustained receptor engagement leads to a positive feedback loop in which ligand-receptor interaction increases expression of the receptor itself on the cell surface (3). However, in normal tissues, RAGE is expressed at low levels (4).Soluble RAGE (sRAGE), a truncated form of...